This is the fourth issue in our series on Clinical Governance in FemTech. So far, we have covered patient safety and risk management, data governance, and patient and user experience.
Today, we turn to clinical effectiveness, the pillar that sits closest to the core promise of any health product.
Most FemTech marketing carries a quiet, built-in claim: backed by science. You’ll find it on landing pages, in pitch decks, and in Instagram captions. And most of the time, it is not a lie. It is just incomplete.
The real question is never whether science exists somewhere in the background but whether that science actually supports what your product claims to do for the women who are actually using it.
What It Actually Means
Clinical effectiveness, applied to FemTech, asks something simple: does your product work reliably, meaningfully, and for the specific population you are serving?
The framework used to answer this question is Evidence-Based Medicine (EBM), the gold standard for clinical decision-making. EBM brings together three things: the best available research evidence, clinical expertise, and the individual patient’s context. When all three align, you have a defensible clinical claim. When only one is present, usually a single study, cited in isolation, you have a problem.
The Friction: Scientific Cherry-Picking
A founder finds a peer-reviewed study, a legitimate research published in a reputable journal, showing that a particular hormonal pattern correlates with a specific symptom. The study gets cited in the pitch deck, on the website, and in the app’s “About” section as validation for a feature now rolling out to hundreds of thousands of users.
What the landing page does not mention is that the study included 22 participants, all between 25 and 32, recruited from a university clinic in a remote area. The users it is now being applied to span different continents, ethnicities, and health histories, for whom the findings may not hold in the same way.
This is scientific cherry-picking. It is not fraud, but it is not clinical effectiveness either.
Women’s bodies are not a monolith. Hormonal norms vary across age, ethnicity, diet, geography, and health history. When FemTech founders use narrow research to make broad clinical promises, they are not lying exactly, but they are not being rigorous either. And in health, the gap between not lying and being rigorous is where people get hurt.
The risk is relational, not just regulatory. Women make real decisions based on what your product tells them, so when the underlying evidence does not hold for them, trust erodes. And in women’s health where trust is already fragile, that erosion is costly.
The Fix: A Clinical Protocol for Every Feature
The solution is not to commission expensive randomized controlled trials before you launch. Most early-stage startups cannot do that. The solution is to build intellectual honesty into the product from the beginning.
This starts with a Clinical Protocol, a living internal document that maps every feature generating a health insight or recommendation back to its evidence base. Think of it as a citation map for your product.
For every insight your app surfaces, the questions should be “What is the source? How large was the study? Who were the participants? Has it been replicated? Does the finding hold across different geographies, ethnicities, and age groups?”
If your app tells a 34-year-old woman in India that her cycle data suggests elevated stress, there should be a documented clinical basis for that inference, not just an algorithm trained on a population that does not reflect her. If the evidence is strong, document it. If it is thin, that gap is telling you something important, either about what your product should not be claiming or about what research you need to commission next.
The protocol protects in two directions. It protects users by ensuring that what the product says is grounded in evidence that is actually relevant to them. And it protects your company, because when you’re asked, “How do you know this works?” you have an honest, auditable answer ready.
More Than Marketing
FemTech has a credibility problem that is partly unfair and partly earned. The field attracts genuine innovators solving real gaps in women’s healthcare. It also attracts founders who have discovered that the word “science” converts very well.
The women using these products are often navigating some of the most consequential moments of their lives, and they are extending trust to a product with decisions that matter deeply.
Hence, clinical effectiveness is the foundational ethical commitment that should precede everything else, before the marketing, pitch deck, or rebrand.
That’s Pillar 4. Next week, we move to Pillar 3 and go even deeper. See you then.
See you then.
Better Woman Health is published weekly.
Subscribe at betterwomanhealth.com to get it directly in your inbox.
Clinical Credibility Toolkit
The Clinical Credibility Toolkit is a free resource designed for FemTech founders building digital tools for women’s health.
It includes the Clinical Credibility Scorecard, a 28-question assessment that helps you identify gaps in your clinical foundation, evidence strategy, safety architecture, and investor readiness, and the Red Flag Detection Checklist, a 25-question assessment that tells you whether your symptom-tracking app can actually detect and act on medical red flags, not just log them.
If you are preparing to pitch, pursuing healthcare partnerships, or simply want to know where your product stands clinically, start here.
Access the toolkit → app.ayomide.me
Thanks for reading. See you soon!
Dr. Ayomide O.
FemTech Credibility Advisor
Find me on LinkedIn or Book a 1:1 Call
